COMMUNIQUÉS West-GlobeNewswire

Sun Biopharma, Inc. Files United States Patent Protecting the Manufacturing Process for Its Lead Drug Candidate, SBP-101

27/02/2018 - 15:00

MINNEAPOLIS, MN, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB:SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, today [...]

OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2017 Financial Results on March 7, 2018

27/02/2018 - 15:00

WARSAW, Ind., Feb. 27, 2018 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (NASDAQ: KIDS ), an orthopedic company focused exclusively on providing a comprehensive product offering to the pediatric orthopedic market, [...]

AXIM Biotech Announces First-Ever Successful Achievement of Proprietary cGMP Extraction and Manufacturing Methods for Pure Cannabinoid Molecules

27/02/2018 - 15:00

NEW YORK, Feb. 27, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies (OTC:AXIM) (“AXIM”), the world leader in cannabinoid research and development, today announced the first-ever successful execution of proprietary current [...]

Coherus BioSciences to Report Fourth Quarter and Full Year 2017 Financial Results on March 8th

27/02/2018 - 15:00

REDWOOD CITY, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS ), today announced that its fourth quarter and full year 2017 financial results will be released after market close on [...]

Data From SELLAS Life Sciences’ Positive Phase 2 Acute Myeloid Leukemia Study Published in American Society of Hematology’s Journal, Blood Advances

27/02/2018 - 14:45

NEW YORK, Feb. 27, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc. (Nasdaq: SLS ) (SELLAS), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer [...]

Transactions in relation to share buyback program

27/02/2018 - 14:33

Acting under its share buyback authorization, the GN Store Nord board of directors initiated a share buyback program on May 4, 2017 in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]

Precision Therapeutics Forms TumorGenesis Inc. Subsidiary to Focus on the Next Generation of Patient Derived Tumor Models

27/02/2018 - 14:30

MINNEAPOLIS, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT ) (“Precision” or “the Company”), formerly Skyline Medical (NASDAQ: SKLN ), a company focused on applying artificial intelligence [...]

BioCryst Reports Fourth Quarter and Full Year 2017 Financial Results

27/02/2018 - 14:30

Updates Investors Regarding Proposed Merger with Idera Pharmaceuticals, Inc. RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) announced today financial [...]

Hemispherx to Present at the Inaugural LD Micro Virtual Conference

27/02/2018 - 14:30

ORLANDO, Fla., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, announced today that it will be presenting at the inaugural LD Micro Virtual [...]

Nuvectra to Present at Two Upcoming Investor Conferences

27/02/2018 - 14:30

PLANO, Texas, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR ), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief [...]

Cerner to Webcast Investment Community Meeting

27/02/2018 - 14:30

KANSAS CITY, Mo., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Cerner (Nasdaq: CERN ) announced today that it will make its 2018 Investment Community Meeting available through a webcast on March 7 th . The webcast will begin at 9: [...]

Dyadic International, Inc. Announces Research and Development Collaboration with Mitsubishi Tanabe Pharma Corporation To Produce Two Target Proteins in C1

27/02/2018 - 14:30

JUPITER, Fla., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform [...]

Eyenovia to Present at the 30th Annual ROTH Conference

27/02/2018 - 14:30

NEW YORK, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Eyenovia Inc. (“Eyenovia”) (NASDAQ: EYEN ), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print [...]

Sarepta Therapeutics to Present at Two Upcoming Investor Conferences

27/02/2018 - 14:30

CAMBRIDGE, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT ), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to [...]

Assure Holdings Corp. Announces Graduation to Tier 1 TSXV Listing

27/02/2018 - 14:30

PARKER, Colo., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “ Company ” or “ Assure ”) (TSXV:IOM) (OTCQB:ARHH), a provider of intraoperative neuromonitoring services, is pleased to announce its [...]

MJ Biotech, Inc. Zen Tea House Increased Sales

27/02/2018 - 14:05

CHEYENNE, Wyo., Feb. 27, 2018 (GLOBE NEWSWIRE) -- MJ Biotech, Inc. (FKA Michael James Enterprises, Inc.) (OTC:MJTV) announced today that Zen Hero, Inc. DBA Zen’s Tea House closed 2017 with sales of over $1,200,000 [...]

Webinar to Reveal Data Supporting the Use of MuScreen™ for Preclinical Immunotherapeutic Development

27/02/2018 - 14:00

SAN DIEGO, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience , a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing [...]

Daré Bioscience, Inc. To Participate in the LD Micro Virtual Conference

27/02/2018 - 14:00

SAN DIEGO, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a clinical-stage, women’s biopharmaceutical company, today announced that Sabrina Martucci Johnson, President and Chief Executive [...]

Zogenix to Release Fourth Quarter and Full-Year 2017 Financial Results and Host Conference Call and Webcast on March 6

27/02/2018 - 14:00

EMERYVILLE, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX ), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that [...]